CRISPR, ViaCyte beat Vertex to the clinic with diabetes cell therapy that evades the immune system
The race to develop a cell therapy for type 1 diabetes is heating up, and the team at ViaCyte and CRISPR Therapeutics appears to have pulled ahead by a hair.
ViaCyte announced Tuesday it’s putting a new therapy in the clinic derived from “off-the-shelf,” gene-edited, immune-evasive stem cells, the first time such a treatment will be tested in humans. The move comes after its clinical trial application was accepted by Canadian regulators, and patient enrollment is expected to start by the end of the year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.